Exercise throughout chemotherapy reduces cognitive impairment, inflammation
the ONA take:
According to a study presented at the 2015 American Society of Clinical Oncology annual meeting this week, researchers from the University of Rochester have found that patients with cancer who exercise throughout chemotherapy had reduced chronic inflammation and cognitive impairment.
For the phase III study, researchers enrolled 619 patients with early-stage cancer. Participants were randomly assigned to receive standard care (no prescribed exercise during chemotherapy) or a specialized program labelled EXCAP. Patients in the EXCAP group walked daily and used resistance bands as instructed while also wearing a pedometer to track steps walked.
Results showed that patients in the standard care group experienced reduced mobility and increased brain fogginess and memory problems. Those patients also had higher levels of blood inflammation. Subgroup analyses showed patients who received chemotherapy in 2-week cycles experienced the most benefit from EXCAP.
"To think that a very simple, low-cost, self-directed exercise prescription can create an anti-inflammatory response similar to a drug and protect against cognitive decline in people with cancer is innovative and very exciting," said Karen M. Mustian, PhD, MPH, associate professor in the University of Rochester Departments of Surgery and Radiation Oncology.
Patients with cancer who exercise throughout chemotherapy had reduced chronic inflammation and cognitive impairment.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|